Cost-effectiveness acceptability curves – caveats quantified

Authors

  • Michał Jakubczyk,

    Corresponding author
    1. Division of Decision Analysis and Support, Warsaw School of Economics, Warsaw, Poland
    2. Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
    • Division of Decision Analysis and Support, Warsaw School of Economics, Al. Niepodległości 164, 02-554 Warsaw, Poland
    Search for more papers by this author
  • Bogumił Kamiński

    1. Division of Decision Analysis and Support, Warsaw School of Economics, Warsaw, Poland
    Search for more papers by this author

Abstract

Cost-effectiveness acceptability curves (CEACs) have become widely used in applied health technology assessment and at the same time are criticized as unreliable decision-making tool. In this paper we show how using CEACs differs from maximizing expected net benefit (NB) and when it can lead to inconsistent decisions. In the case of comparing two alternatives we show the limits of the discrepancy between CEAC and expected NB approach and link it with expected value of perfect information. We also show how the shape of CEAC is influenced by the skewness of estimate of expected NB distribution, the correlation between cost and effect estimates and their variance. In the case of more than two options we show when using CEACs can lead to non-transitive choices in pair-wise comparisons and when it lacks independence of irrelevant alternatives property in joint comparisons. Copyright © 2009 John Wiley & Sons, Ltd.

Ancillary